Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

Haematologica

Volumn 101, Issue 5, 2016, Pages 626-633

  Ruggeri, Loredana ^a   Urbani, Elena ^a   André, Pascale ^b   Mancusi, Antonella ^a   Tosti, Antonella ^a   Topini, Fabiana ^a   Bléry, Mathieu ^b   Animobono, Lucia ^a   Romagné, François ^c   Wagtmann, Nicolai ^b   Velardi, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b INNATE PHARMA   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2A ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; MONOCLONAL ANTIBODY; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOTOXICITY ASSAY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; MORTALITY; PATHOLOGY; PROCEDURES; TRANSFORMED CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; CELL LINE, TRANSFORMED; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C;

EID: 84964787439     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.135301     Document Type: Article

References (26)

1. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331 (6013):44-49.
2. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
3. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23(2): 255-259.
4. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339.
5. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
6. Karre K. A perfect mismatch. [commentary] Science. 2002;295(5562):2029-2031.
7. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433-440.
8. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol. 2009;21(5):525-530.
9. Pende D, Marcenaro S, Falco M, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119-3129.
10. Romagne F, Andre P, Spee P, et al. Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.
11. Sola C, André P, Lemmers C, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci USA. 2009;106 (31):12879-12884.
12. Benson DM, Jr Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118 (24):6387-6391.
13. Kohrt HE, Thielens A, Marabelle A, et al. Anti-KIR antibody enhancement of antilymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123(5): 678-686.
14. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317-4323.
15. Stern M, De Angelis C, Urbani E, et al. Natural killer cell KIR repertoire reconstitution after haploidentical stem cell transplantation. Bone Marrow Transplant. 2010; 45(11):1607-1610.
16. Godal R, Bachanova V, Gleason M, et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010;16(5):612-621.
17. Nguyen S, Dhedin N, Vernant JP, et al. NKcell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105(10):4135-4142.
18. Moretta A, Vitale M, Sivori S, et al. Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. J Exp Med. 1994;180(2):545-555.
19. Mancusi A, Ruggeri L, Urbani E, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces non relapse mortality. Blood. 2015;125(20):3173-82.
20. André MC, Erbacher A, Gille C, et al. Longterm human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells. J Immunol. 2010;185(5):2710-2720.
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
22. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-959.
23. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273-3279.
24. Son SW, Kim EO, Ryu ES, et al. Upregulation of Fas and downregulation of CD94⁄NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. Br J Dermatol. 2009;161(2):281-288.
25. Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H. Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci USA. 2011;108(35):14584-14589.
26. Seymour L, Tinker A, Hirte H, Wagtmann N, Dodion P. Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Ann Oncol. 2015;26 (Suppl. 2):ii3-ii5.